{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:56:07Z","timestamp":1777600567110,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jneuroim.2020.577383","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T11:28:35Z","timestamp":1600169315000},"page":"577383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients"],"prefix":"10.1016","volume":"348","author":[{"given":"Huahua","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2020.577383_bb0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/1756-185X.13338","article-title":"MiR-146a levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis","volume":"21","author":"Bae","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and consequences of miR-150-5p dysregulation in myasthenia gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","author":"Di Stefano","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0035","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.4049\/jimmunol.0901187","article-title":"C-Myb is required for pro-B cell differentiation","volume":"183","author":"Fahl","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0040","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/08916934.2015.1072518","article-title":"MicroRNA-150: a potential regulator in pathogens infection and autoimmune diseases","volume":"48","author":"Huang","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2020.577383_bb0070","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2018.04.016","article-title":"Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets","volume":"428","author":"Long","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis","volume":"555","author":"Lu","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0090","article-title":"Low-dose rituximab every 6months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis","author":"Lu","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01500","article-title":"Non-Exosomal and Exosomal circulatory MicroRNAs: which are more valid as biomarkers?","volume":"10","author":"Nik Mohamed Kamal","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113842","article-title":"Ectopic MicroRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells","volume":"9","author":"Palagani","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0145","article-title":"Refractory myasthenia gravis \u2013 clinical profile, comorbidities and response to rituximab","volume":"14","author":"Sudulagunta","year":"2016","journal-title":"Ger. Med. Sci."},{"key":"10.1016\/j.jneuroim.2020.577383_bb0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2007.07.021","article-title":"MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb","volume":"131","author":"Xiao","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2020.577383_bb0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imm.12347","article-title":"Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis","volume":"144","author":"Zhang","year":"2015","journal-title":"Immunology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820303994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820303994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:38:57Z","timestamp":1759048737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820303994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"alternative-id":["S0165572820303994"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577383","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577383"}}